BLZ945 CSF1R Inhibitor: Research Guidelines & Applications

BLZ945 is a potent, selective, orally bioavailable small-molecule inhibitor of colony-stimulating factor 1 receptor (CSF1R) widely used in research to deplete tumor-associated macrophages and investigate the role of CSF1R signaling in the tumor microenvironment and inflammatory diseases.

Target

CSF1R (Colony-Stimulating Factor 1 Receptor, also known as CD115 or c-Fms)

Compound Class

ATP-competitive small-molecule kinase inhibitor

Primary Research Application

Macrophage depletion, tumor-associated macrophage (TAM) targeting, neuroinflammation research

Route of Administration (in vivo)

Oral gavage (commonly formulated in vehicles such as PEG400/water or methylcellulose)

Storage

Store at -20 °C, protected from light and moisture; confirm with product datasheet

Solubility

Soluble in DMSO; limited aqueous solubility — consult datasheet for confirmed values

Mechanism of Action

BLZ945 exerts its pharmacological effect by competitively inhibiting the ATP-binding site of CSF1R, a receptor tyrosine kinase (RTK) encoded by the CSF1R gene. CSF1R is activated upon binding of its two primary ligands, colony-stimulating factor 1 (CSF1/M-CSF) and interleukin-34 (IL-34). Ligand binding triggers receptor dimerization, autophosphorylation, and downstream activation of survival and proliferation pathways including PI3K/AKT and RAS/MAPK.

By blocking CSF1R kinase activity, BLZ945 prevents receptor autophosphorylation, thereby inhibiting downstream signaling and depriving macrophages, monocytes, and microglia of critical survival and differentiation signals. This results in selective depletion or functional impairment of CSF1R-dependent myeloid populations without broadly suppressing lymphocyte function, making BLZ945 a preferred tool compound for dissecting myeloid contributions to disease pathology.

Preparation and Formulation Guidelines

Stock Solution Preparation: BLZ945 is most commonly dissolved in dimethyl sulfoxide (DMSO) to prepare a concentrated stock solution (e.g., 10–50 mM). Vortex thoroughly and, if necessary, apply gentle warming (37 °C water bath) to aid complete dissolution. Verify solubility against the Certificate of Analysis (CoA) for your specific lot.

In Vitro Working Solutions: Dilute the DMSO stock into aqueous cell culture medium immediately before use. Ensure the final DMSO concentration does not exceed 0.1% (v/v) to avoid solvent cytotoxicity. Prepare fresh working solutions for each experiment. Include a DMSO vehicle control at matching concentration.

In Vivo Formulations: For oral administration in rodent studies, BLZ945 is commonly formulated in polyethylene glycol 400 (PEG400) / water mixtures or in 0.5% methylcellulose aqueous suspension. The specific concentration and vehicle should be optimized based on the target dose and animal model. Always filter-sterilize formulations intended for administration and confirm chemical stability of the prepared formulation prior to dosing.

Note: Formulation details should be validated against the current product datasheet and relevant primary literature before initiating in vivo studies.

Experimental Applications and Protocols

Tumor-Associated Macrophage (TAM) Depletion: BLZ945 is extensively used in syngeneic and genetically engineered mouse tumor models to deplete TAMs and assess the functional consequences on tumor growth, angiogenesis, and response to immunotherapy. Researchers typically administer BLZ945 orally via daily gavage and monitor macrophage depletion efficiency by flow cytometry using markers such as CD11b, F4/80, and CSF1R.

In Vitro Macrophage Survival and Differentiation Assays: BLZ945 can be applied to bone marrow-derived macrophages (BMDMs) or monocyte-derived macrophages cultured in M-CSF to assess the role of CSF1R signaling in survival, proliferation, and polarization. Dose-response experiments across a concentration range (e.g., 0.01–10 µM) are recommended to establish IC50 values under your specific experimental conditions.

Neuroinflammation and Microglia Research: CSF1R is a key survival receptor for microglia. BLZ945 has been used in preclinical models to deplete microglia and study their roles in neurodegenerative diseases, brain injury, and CNS tumor biology. Intracranial penetration should be confirmed with pharmacokinetic data appropriate to the study model.

Controls and Validation: Always include (1) a vehicle-only control, (2) an isotype or fluorescence-minus-one (FMO) control for flow cytometry panels, and (3) a positive depletion control where feasible. Confirm macrophage depletion at the experimental endpoint using validated antibody panels.

Safety, Handling, and Regulatory Considerations

General Laboratory Safety: BLZ945 is supplied for research use only (RUO) and is not intended for diagnostic, therapeutic, or human use. Handle according to standard laboratory safety practices for small-molecule compounds. Wear appropriate personal protective equipment (PPE) including nitrile gloves, lab coat, and safety glasses.

DMSO Considerations: When preparing solutions in DMSO, be aware that DMSO rapidly penetrates skin and may carry dissolved compounds transdermally. Avoid skin contact with DMSO stock solutions of BLZ945. Use chemical-resistant gloves.

Waste Disposal: Dispose of BLZ945, its solutions, and contaminated materials according to your institutional chemical waste disposal guidelines and all applicable local, national, and international regulations.

SDS Reference: Consult the Safety Data Sheet (SDS) provided with your Aladdin Scientific shipment or available on the product page for comprehensive hazard information before handling.

Quality Control and Troubleshooting

Purity Verification: Each lot of BLZ945 from Aladdin Scientific is accompanied by a Certificate of Analysis (CoA) detailing purity (typically assessed by HPLC) and identity (confirmed by NMR and/or MS). Review the CoA upon receipt and retain records for experimental traceability.

Aliquoting to Avoid Freeze-Thaw Cycles: Prepare single-use aliquots of the DMSO stock solution upon first reconstitution. Repeated freeze-thaw cycles can reduce compound integrity. Store aliquots at -20 °C under inert atmosphere (e.g., argon or nitrogen blanket) if long-term storage is required.

Common Troubleshooting Issues:

• Incomplete macrophage depletion: Verify dosing regimen and confirm CSF1R expression on target cell population by flow cytometry before treatment.
• Precipitation in aqueous media: Reduce DMSO stock concentration, pre-warm medium, or use a co-solvent such as Tween-80 at minimal concentrations as appropriate.
• Unexpected cell toxicity: Check final DMSO concentration; perform cell viability assays with vehicle controls to distinguish compound effects from solvent effects.
• Loss of activity over time: Check storage conditions; prepare fresh working solutions; confirm compound integrity with HPLC if activity loss is suspected.

Frequently asked questions

What is the primary research use of BLZ945?

BLZ945 is primarily used as a selective CSF1R inhibitor to deplete macrophages and monocytes in vitro and in vivo, enabling researchers to study the role of these myeloid cells in tumor biology, neuroinflammation, and other disease contexts. It is a key tool compound in tumor microenvironment research targeting tumor-associated macrophages (TAMs).

How should BLZ945 stock solutions be prepared and stored?

BLZ945 should be dissolved in DMSO to prepare a concentrated stock solution, as it has limited aqueous solubility. Aliquot the stock into single-use volumes to avoid repeated freeze-thaw cycles and store at -20 °C, protected from light and moisture. Always refer to the Aladdin Scientific product datasheet and CoA for lot-specific solubility and storage recommendations.

What controls should be included when using BLZ945 in macrophage depletion experiments?

Essential controls include a DMSO vehicle-only control (matched to the final solvent concentration in treated samples), appropriate isotype or FMO controls for flow cytometry validation of depletion, and where feasible a positive control. Macrophage depletion efficiency should be confirmed at the experimental endpoint using validated surface markers such as CD11b, F4/80, and CSF1R by flow cytometry.

Is BLZ945 selective for CSF1R over other kinases?

BLZ945 is reported in the literature to exhibit selectivity for CSF1R; however, as with most kinase inhibitors, off-target activity at other kinases may occur at higher concentrations. Researchers should consult the primary literature and kinase selectivity profiling data and use the lowest effective concentration to minimize off-target effects.

Can BLZ945 penetrate the blood-brain barrier for microglia depletion studies?

BLZ945 has been used in preclinical studies involving central nervous system (CNS) models, and some published studies report evidence of CNS penetration sufficient for microglial depletion. However, CNS bioavailability can be model- and formulation-dependent. Researchers should validate intracranial drug exposure with appropriate pharmacokinetic studies for their specific experimental system.

References

1. Pyonteck SM, et al. CSF1R inhibition with a next-generation therapeutic agent leads to regression of established glioblastoma. Nature Medicine. 2013.
2. Quail DF, et al. The tumor microenvironment underlies acquired resistance to CSF1R inhibition in gliomas. Science. 2016.
3. Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.